Newsroom | 27304 results

AUCKLAND, New Zealand--(BUSINESS WIRE)--HPE (NYSE:HPE) today announced that Earth Sciences New Zealand (formally NIWA) of Aotearoa (New Zealand) selected HPE Cray XD2000, purpose-built for AI and simulation workloads, to accelerate the organization’s environmental science and precision of meteorological forecasting. The new system, named Cascade, replaces Earth Sciences New Zealand’s aging high performance computing (HPC) and delivers a threefold increase in computational power for researchers...

ROCKVILLE, Md.--(BUSINESS WIRE)--BIOQUAL, Inc. www.bioqual.com BIOQ(Pinksheets):     2025     2024   Revenue $ 48,867,753   $ 58,590,949   (Loss) Income Before Income Tax $ (1,896,010 ) $ 476,447   Net (Loss) Income $ (1,048,154 ) $ 483,481   Basic Earnings per Share of Common Stock $ (1.17 ) $ .54   Diluted Earnings per Share of Common Stock $ (1.17 ) $ .54   Weighted Average           Number of Shares Outstanding           For Basic Earnings Per Share   894,416     894,416   Weighted Average...

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease....

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that it has been named to the prestigious 2025 Endpoints 11 list. The Endpoints 11 annually recognizes the most promising private biotech companies in the world driving innovation and shaping the future of the industry. “We are thrilled to receive this recognition after just...

NANNING, China--(BUSINESS WIRE)--From September 17 to 19, the 4th China-ASEAN Meteorological Cooperation Forum kicked off in Nanning, Guangxi. Decision-makers, experts, and scholars from meteorological and hydrological departments of China and ASEAN countries such as Brunei, Cambodia, Laos, Vietnam, Thailand, Myanmar, and Indonesia, as well as from the World Meteorological Organization (WMO), universities, enterprises, and research institutions, gathered to discuss regional meteorological coope...

MINNEAPOLIS--(BUSINESS WIRE)--A study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) found that a donor search prognosis-based strategy helps physicians move patients with blood cancers and other blood diseases to hematopoietic cell transplant (HCT) faster, resulting in similar transplant success regardless of likelihood of finding a matched unrelated donor (MUD). Investigators from the consortium of U.S. transplant centers, CIBMTR® (Center for International Blood and Marr...

NEW YORK--(BUSINESS WIRE)--Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented results from a cross-sectional retrospective study of more than 75,000 respondents from the 2022 National Health and Wellness Survey at the Psych Congress 2025. The analysis found that nearly half (48%) of respondents with severe GAD symptoms repo...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for KEYTRUDA® (pembrolizumab), which if approved would be marketed in...

TORONTO--(BUSINESS WIRE)--Celltrion annonce aujourd'hui que Santé Canada a approuvé le Stoboclo™ et l'Osenvelt™ (CT-P41), des biosimilaires faisant référence au Prolia® et au Xgeva®, respectivement, pour toutes les indications de produits de référence.1,2 « L’approbation de Stoboclo et Osenvelt souligne notre engagement à développer des thérapies centrées sur le patient, en particulier pour les formes incurables de maladies telles que l’ostéoporose, où les patients sont confrontés à des pronost...

TORONTO--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Stoboclo® and Osenvelt® (CT-P41), biosimilars referencing Prolia® and Xgeva®, respectively for all indications of reference products.1,2 “The approval of Stoboclo and Osenvelt underscores our commitment to developing patient-centric therapies, particularly for incurable forms of disease such as osteoporosis where patients face difficult prognoses,” said Jungyong Shin, Managing Director at Celltrion Healthcare Ca...